Wellorithm Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6/10
Best for: compounded semaglutide at $247/month
Wellorithm falls below our bar on medical oversight. Read the breakdown below before you give it money.
then $247/mo ongoing
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Louisiana is the single state Wellorithm does not reach; the other 49 it does. Compounded semaglutide and compounded tirzepatide come as injectables or as oral dissolving tablets. Board-certified obesity specialists run the virtual consultations, with support on hand 24/7. This GLP-1 telehealth operation is based in Miami.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Wellorithm
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Wellorithm at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $147/mo (Not displayed on marketing pages; from the site's own public checkout catalog: $247/mo standing with '$100 off your f...)
- Availability
- 49 states
- FDA status
- No FDA warning letter on record
How Wellorithm scores
Six columns, each one computed from something Wellorithm has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.1/10$247/month is 31% above the register median of $189 for compounded semaglutide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
3.0/10On the seller's own pages, no price appears until the medical intake is finished.
Trust & Safety15%
5.0/10does not name a dispensing pharmacy; withholds price until after the intake; publishes its state list. Our verification confidence is medium.
Accessibility10%
9.8/10Publishes coverage in 49 of 50 states.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Wellorithm
Last checked July 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Wellorithm involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Wellorithm does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Wellorithm does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- Cheapest standing monthly prices on record: semaglutide $247, tirzepatide $349. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 49 of 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Wellorithm support, as documented
- Phone
- +1 (877) 402-6778
- Hours
- 24/7
GLP-1 medications Wellorithm offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Not displayed on marketing pages; from the site's own public checkout catalog: $247/mo standing with '$100 off your first month' ($147), 3-month bundle $645 ($215/mo).
From the site's own public checkout catalog: $349/mo standing, $249 first month ($100 off), 3-month bundle $947 (~$316/mo).
Check the price yourself before you pay
Every figure here was read off Wellorithm's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $247 a month, within the normal band around this register's $189 median for the same drug and form
- Coverage is published for 49 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Wellorithm charges
Wellorithm advertises $147. That buys the first month. The standing rate is $247/month, and that is the one worth doing arithmetic on, because the introductory figure applies once.
- Compounded semaglutide — $147 first month, then $247/month
- Compounded tirzepatide — $249 first month, then $349/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Discounting the first month does not change the twelve-month total by much.
Breeze Meds dispenses semaglutide and tirzepatide from $199/month, which makes it the honest comparison to run before committing here.
What Wellorithm dispenses
Wellorithm prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at Wellorithm at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a demonstrated equal to the shot.
What we could verify
On the record: it treats patients in all 50 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You would be choosing on the advertised figure. The introductory month is real, but it is not what you will be paying in month three.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want a cheap way to find out whether the medication suits you before committing
- injections are the thing keeping you from starting
- you need access regardless of where you live
Our read
Wellorithm is a cheap way to start and an ordinary way to continue. Use the $147 month for what it is good for — establishing whether the medication works for you — and re-run the numbers against $247/month before you let it renew twice. Direct Meds is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
Wellorithm falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Wellorithm
Starting at $147/month. Check today's price, then book the free consultation.
Where Wellorithm is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Wellorithm review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Wellorithm's current pricing
Plans start at $147/month. The free consultation is where you learn whether you qualify, and what it costs today.